Qualigen Therapeutics, Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- AIxCrypto Holdings, Inc., formerly known as Qualigen Therapeutics, Inc., is undergoing a significant strategic transition, evolving from a clinical-stage biotechnology company into a Web3 and AI-driven technology platform. While previously dedicated to advancing novel therapeutic products for cancer, the company is now establishing itself as a gateway to the AI x Web3 ecosystem. In its former capacity, the company developed pipeline candidates such as QN-302, a small molecule G-quadruplex (G4)-selective transcription inhibitor in Phase 1 clinical trials for pancreatic and other solid tumors, which has secured global patents extending into 2040. Other investigational oncology programs included the Pan-RAS (formerly RAS-F) family of small molecule inhibitors targeting mutated RAS oncogenes prevalent in various cancers, and QN-247, a DNA-coated gold nanoparticle drug candidate demonstrating efficacy in preclinical models for triple-negative breast cancer. The company notably divested its FastPack® diagnostic business in July 2023 to refocus on its therapeutic pipeline. Now, under its new identity, AIxCrypto Holdings is focused on a "Three Driving Forces" strategy. Key initiatives include developing the BesTrade DeAI Agent and a Web3 AI Terminal for on-chain trading, building an RWA (Real World Asset) + EAI (Embodied AI) ecosystem with plans for tokenized stock projects, and providing AI-driven crypto asset management, including a C10 index. This strategic pivot is supported by significant financing, including a $41 million PIPE investment led by Faraday Future, making them a majority shareholder, and a partnership with BitGo for multi-asset crypto treasury allocation. The company was founded in 1996 and maintains its base in Carlsbad, California.
Qualigen Therapeutics Stockholders Approve All Proposals with Majority Vote; Company to Rebrand as AIxCrypto Holdings, Inc. (Nasdaq: AIXC) Following November 20 Nasdaq Ceremony and Announces Transition into AI × Web3 Strategy
Qualigen Therapeutics to Rebrand as AIxCrypto After Stockholder Meeting on November 12, with Three Core Goals for 2025
Biotech Stocks To Add to Your Watchlist – October 24th
Qualigen Therapeutics (QLGN) Stock Soars 62% After-Hours On Partnership With BitGo To Build Multi-Asset Crypto Treasury
Qualigen Therapeutics Partners with BitGo to Execute First Multi-Asset C10 Treasury Allocation
Qualigen Therapeutics Announces the Official Launch of C10 Cryptocurrency Asset Treasury (DAT) Purchases: Why Is This Pullback the Golden Moment CXC10 Has Been Waiting For?
Qualigen Therapeutics (NASDAQ: QLGN) Announces Executives, Board of Directors Appointments and Auditor Transition
Univest Securities, LLC Announces Closing of $41 Million Strategic Investment in Client Qualigen Therapeutics (NASDAQ: QLGN) from Client Faraday Future (NASDAQ: FFAI)
Qualigen Therapeutics Announces Successful Closing of $41 Million PIPE Financing Led by Faraday Future, Accelerating New Business Transformation into Crypto
Faraday Future Announces Closing of Strategic $41 Million Investment in Qualigen Therapeutics (NASDAQ: QLGN) to Accelerate its Dual-Flywheel & Dual-Bridge Eco Strategy
Faraday Future Announced a Total Strategic Investment of $41 million in Qualigen Therapeutics, Inc. (NASDAQ: QLGN) During its Annual 919 Event, for its Crypto Business Focusing on Three Growth Engines
Faraday Future Announces Strategic $41 Million Investment in Qualigen Therapeutics, Inc. (NASDAQ: QLGN) for Crypto Business Through PIPE Transaction
Faraday Future Announces Strategic $41 Million Investment in Qualigen Therapeutics, Inc. (NASDAQ: QLGN) f for Crypto Business Through PIPE Transaction
Qualigen Therapeutics Announces $4.5 Million Private Placement of Series A-3 Convertible Preferred Stock
Qualigen Granted New Patents Covering 25 Countries
Qualigen Therapeutics, Inc. receives expected notification of deficiency from Nasdaq related to delayed filing of quarterly report on Form 10-Q
Qualigen Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Annual Report on Form 10-K
Univest Securities, LLC Announces Successful Closing of $5.1 Million Private Placement for Qualigen Therapeutics, Inc. (NASDAQ: QLGN)
Shares Expected to Begin Trading on Split-Adjusted Basis on November 5, 2024
Qualigen Therapeutics, Inc. Announces management changes.